Joint injury and osteoarthritis: Soluble mediators in the course and treatment of cartilage pathology

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 435-445

  Rutgers, Marijn ^a   Saris, Daniël B F ^a   Yang, Kiem Gie Auw ^a   Dhert, Wouter J A ^a,b   Creemers, Laura B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cartilage; Cytokine; Intra articular trauma; Osteoarthritis; Synovial fluid

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

CHONDROGENESIS; CYTOKINE PRODUCTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; JOINT INJURY; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNOVIAL FLUID;

ANIMALS; CARTILAGE; CHONDROITIN SULFATES; CYTOKINES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; KNEE INJURIES; KNEE JOINT; OSTEOARTHRITIS; RISK FACTORS; SYNOVIAL FLUID;

EID: 77953462201     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.14     Document Type: Review

References (153)

1. Roitt IM, Brostoff J, Male DK: Cell-mediated immune reactions. In: Immunology. Crowe L (Ed.). Mosby, London, UK 121-138 (2001).
2. Garlet TP, Coelho U, Silva JS, Garlet GP: Cytokine expression pattern in compression and tension sides of the periodontal ligament during orthodontic tooth movement in humans. Eur. J. Oral Sci. 115(5), 355-362 (2007).
3. Graves D: Cytokines that promote periodontal tissue destruction. J. Periodontol. 79(Suppl. 8), 1585-1591 (2008).
4. Gharaee-Kermani M, Phan SH: Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr. Pharm. Des. 7(11), 1083-1103 (2001).
5. Matsumoto K, Ikema K, Tanihara H: Role of cytokines and chemokines in pseudomonal keratitis. Cornea 24(Suppl. 8), S43-S49 (2005). (Pubitemid 41688555)
6. Blanchard F, Duplomb L, Baud'huin M, Brounais B: The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev. (2008).
7. Goldring MB, Berenbaum F: The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin. Orthop. Relat. Res. (Suppl 427), S37-S46 (2004).
8. Goldring SR, Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin. Orthop. Relat. Res. (Suppl. 427), S27-36 (2004). ■■ Excellent review on the role of a variety of cytokines in cartilage damage and repair.
9. Buckwalter JA, Einhorn TA, Simon SB: Articular cartilage structure, composition, and function. In: Orthopaedic Basic Science. American Academy of Orthopaedic Surgeons, Rosemont, IL, USA 444-451 (1999). ■ Comprehensive reference work on composition and biomechanical properties of cartilage.
10. Yaron I, Meyer FA, Dayer JM, Bleiberg I, Yaron M: Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures. Arthritis Rheum. 32(2), 173-180 (1989). (Pubitemid 19056405)
11. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM: Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J. Clin. Invest. 82(6), 2026-2037 (1988).
12. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E: Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheumatol. 14(2), 155-162 (1996).
13. Westacott CI, Whicher JT, Barnes IC et al.: Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann. Rheum. Dis. 49(9), 676-681 (1990).
14. Rooney M, Symons JA, Duff GW: Interleukin 1 β in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol. Int. 10(5), 217-219 (1990).
15. Cohen SB, Moreland LW, Cush JJ et al.: A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret®), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63(9), 1062-1068 (2004).
16. Moreland LW, Weinblatt ME, Keystone EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. 33(5), 854-861 (2006).
17. Nishimoto N, Hashimoto J, Miyasaka N et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162-1167 (2007).
18. Blom AB, van der Kraan PM, van den Berg WB: Cytokine targeting in osteoarthritis. Curr. Drug Targets 8(2), 283-292 (2007).
19. Loyau G, Pujol JP: The role of cytokines in the development of osteoarthritis. Scand. J. Rheumatol. (Suppl. 81) 8-12 (1990).
20. Furuzawa-Carballeda J, Macip-Rodriguez PM, Cabrai AR: Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response. Clin. Exp. Rheumatol. 26(4), 554-560 (2008).
21. Cope AP: T cells in rheumatoid arthritis. Arthritis Res. Ther. (10 Suppl. 1) S1 (2008).
22. Gelber AC, Hochberg MC, Mead LA et al.: Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann. Intern. Med. 133(5), 321-328 (2000).
23. Sherman MF, Warren RF, Marshall JL, Savatsky GJ: A clinical and radiographical analysis of 127 anterior cruciate insufficient knees. Clin. Orthop. Relat. Res. 227, 229-237 (1988).
24. Rangger C, Kathrein A, Klestil T, Glotzer W: Partial meniscectomy and osteoarthritis. Implications for treatment of athletes. Sports Med. 23(1), 61-68 (1997).
25. Cameron ml, Fu FH, Paessler HH, Schneider M, Evans CH: Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee. Knee Surg. Sports Traumatol. Arthrosc. 2(1), 38-44 (1994).
26. Smith RL, Allison AC, Schurman DJ: Induction of articular cartilage degradation by recombinant interleukin 1 α and 1 β. Connect Tissue Res. 18(4), 307-316 (1989).
27. Pettipher ER, Higgs GA, Henderson B: Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. U.S.A. 83(22), 8749-8753 (1986).
28. Westacott CI, Barakat AF, Wood L et al.: Tumor necrosis factor α can contribute to focal loss of cartilage in osteoarthritis. Osteoarthr. Cartil. 8(3), 213-221 (2000).
29. Henrotin YE, De Groote DD, Labasse AH et al.: Effects of exogenous IL-1 β, TNF α, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthr. Cartil. 4(3), 163-173 (1996).
30. Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin. Exp. Immunol. 75(2), 306-310 (1989).
31. Stove J, Huch K, Gunther KP, Scharf HP: Interleukin-1β induces different gene expression of stromelysin, aggrecan and tumor-necrosis-factor- stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology 68(3), 144-149 (2000). (Pubitemid 32110323)
32. Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology, 39(1-2), 237-246 (2002).
33. Arend WP: The balance between IL-1 and IL-1RA in disease. Cytokine Growth Factor Rev. 13(4-5), 323-340 (2002). ■ In addition to this specific review on the role of IL-1 and its receptor, earlier work by Arend is very constructive in explaining mechanisms of action of IL-1.
34. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT: Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300(1-2), 124-135 (2005). (Pubitemid 40805593)
35. Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38(2), 151-160 (1995).
36. Henrotin YE, Zheng SX, Labasse AH et al.: Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthr. Cartil. 8(6), 474-482 (2000).
37. Jovanovic DV, Di Battista JA, Martel-Pelletier J et al.: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160(7), 3513-3521 (1998). (Pubitemid 28164746)
38. Durigova M, Roughley PJ, Mort JS: Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthr. Cartil. 16(1), 98-104 (2008).
39. Koshy PJ, Lundy CJ, Rowan AD et al.: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 46(4), 961-967 (2002).
40. Long D, Blake S, Song XY, Lark M, Loeser RF: Human articular chondrocytes produce IL-7 and respond to IL-7 with increased production of matrix metalloproteinase-13. Arthritis Res. Ther. 10(1), R23 (2008).
41. Merz D, Liu R, Johnson K, Terkeltaub R: IL-8/CXCL8 and growth-related oncogene α/CXCL1 induce chondrocyte hypertrophic differentiation. J. Immunol. 171(8), 4406-4415 (2003). (Pubitemid 37238720)
42. Lotz M, Moats T, Villiger PM: Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J. Clin. Invest. 90(3), 888-896 (1992).
43. Flannery CR, Little CB, Hughes CE et al.: IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol. 19(6), 549-553 (2000).
44. Nietfeld JJ, Wilbrink B, Helle M et al.: Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum. 33(11), 1695-1701 (1990).
45. Villiger PM, Kusari AB, ten Dijke P, Lotz M: IL-1 β and IL-6 selectively induce transforming growth factor-β isoforms in human articular chondrocytes. J. Immunol. 151(6), 3337-3344 (1993).
46. Lotz M, Guerne PA: Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA).J. Biol. Chem. 266(4), 2017-2020 (1991).
47. Loeser RF, Chubinskaya S, Pacione C, Im HJ: Basic fibroblast growth factor inhibits the anabolic activity of insulin-like growth factor 1 and osteogenic protein 1 in adult human articular chondrocytes. Arthritis Rheum. 52(12), 3910-3917 (2005). (Pubitemid 41798230)
48. Vincent T, Hermansson M, Bolton M, Wait R, Saklatvala J: Basic FGF mediates an immediate response of articular cartilage to mechanical injury. Proc. Natl Acad. Sci. U.S.A. 99(12), 8259-8264 (2002).
49. Guerne PA, Sublet A, Lotz M: Growth factor responsiveness of human articular chondrocytes: distinct profiles in primary chondrocytes, subcultured chondrocytes, and fibroblasts. J. Cell Physiol. 158(3), 476-484 (1994). (Pubitemid 24094429)
50. Alaaeddine N, Di Battista JA, Pelletier JP et al.: Inhibition of tumor necrosis factor α-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum. 42(4), 710-718 (1999). (Pubitemid 29171991)
51. Arend WP, Welgus HG, Thompson RC, Eisenberg SP: Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85(5), 1694-1697 (1990).
52. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW: Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. 9(1), 12-20 (2002).
53. Granowitz EV, Clark BD, Mancilla J, Dinarello CA: Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J. Biol. Chem. 266(22), 14147-14150 (1991).
54. Smith RJ, Chin JE, Sam LM, Justen JM: Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum. 34(1), 78-83 (1991).
55. Secombes C, Zou J, Daniels G et al.: Rainbow trout cytokine and cytokine receptor genes. Immunol. Rev. 166, 333-340 (1998).
56. van Osch GJ, van den Berg WB, Hunziker EB, Hauselmann HJ: Differential effects of IGF-1 and TGF β-2 on the assembly of proteoglycans in pericellular and territorial matrix by cultured bovine articular chondrocytes. Osteoarthr. Cartil. 6(3), 187-195 (1998).
57. Lafeber FP, van Roy HL, van der Kraan PM, van den Berg WB, Bijlsma JW: Transforming growth factor-β predominantly stimulates phenotypically changed chondrocytes in osteoarthritic human cartilage. J. Rheumatol. 24(3), 536-542 (1997).
58. Regan EA, Bowler RP, Crapo JD: Joint fluid antioxidants are decreased in osteoarthritic joints compared with joints with macroscopically intact cartilage and subacute injury. Osteoarthr. Cartil. 16(4), 515-521 (2008).
59. Scharstuhl A, Glansbeek HL, van Beuningen HM et al.: Inhibition of endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J. Immunol. 169(1), 507-514 (2002). (Pubitemid 34686173)
60. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ: Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J. Bone Joint Surg. Br. 89(5), 672-685 (2007).
61. Fortier LA, Mohammed HO, Lust G, Nixon AJ: Insulin-like growth factor-I enhances cell-based repair of articular cartilage. J. Bone Joint Surg. Br. 84(2), 276-288 (2002).
62. Fukumoto T, Sperling JW, Sanyal A et al.: Combined effects of insulin-like growth factor-1 and transforming growth factor-β1 on periosteal mesenchymal cells during chondrogenesis in vitro. Osteoarthr. Cartil. 11(1), 55-64 (2003).
63. Tsukazaki T, Matsumoto T, Enomoto H et al.: Growth hormone directly and indirectly stimulates articular chondrocyte cell growth. Osteoarthr. Cartil. 2(4), 259-267 (1994).
64. Kong YY, Feige U, Sarosi I et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759), 304-309 (1999).
65. Shimizu S, Asou Y, Itoh S et al.: Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum. 56(10), 3358-3365 (2007). (Pubitemid 47585430)
66. Takemura M, Harada A, Mizuno M, Yano K, Yamada Y: Relationship between osteoprotegerin/osteodastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. Metabolism 50(1), 1-2 (2001). (Pubitemid 32058540)
67. Cohen NP, Foster RJ, Mow VC: Composition and dynamics of articular cartilage: structure, function, and maintaining healthy state. J. Orthop. Sports Phys. Ther. 28(4), 203-215 (1998).
68. Junqueira LC, Carneiro J, Kelley RO: Cartilage. In: Basic Histology. Elsevier, Maarssen, The Netherlands, 126-136 (1996)
69. Homandberg GA: Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. Front Biosci. 4, D713-D730 (1999).
70. Carnemolla B, Cutolo M, Castellani P et al.: Characterization of synovial fluid fibronectin from patients with rheumatic inflammatory diseases and healthy subjects. Arthritis Rheum. 27(8), 913-921 (1984). (Pubitemid 14067787)
71. Xu L, Peng H, Wu D et al.: Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J. Biol. Chem. 280(1), 548-555 (2005).
72. Xu L, Peng H, Glasson S et al.: Increased expression of the collagen receptor discoidin domain receptor 2 in articular cartilage as a key event in the pathogenesis of osteoarthritis. Arthritis Rheum. 56(8), 2663-2673 (2007). (Pubitemid 47237284)
73. Iwanaga T, Shikichi M, Kitamura H, Yanase H, Nozawa-Inoue K: Morphology and functional roles of synoviocytes in the joint. Arch. Histol. Cytol. 63(1), 17-31 (2000).
74. Junqueira LC, Carneiro J, Kelley RO: Bone tissue. In: Basic Histology. Elsevier, Maarssen, The Netherlands, 137-162 (1996).
75. Henderson B, Edwards JCW (Eds): Structure of synovial lining. In: The Synovial Lining in Health and Disease. Chapman and Hall Medical, Cambridge, UK 17-40 (1987).
76. Ropes MW, Rossmeisl EC, Bauer W: The origin and nature of normal human synovial fluid. J. Clin. Invest. 19(6), 795-799 (1940).
77. Heilmann HH, Lindenhayn K, Walther HU: [Synovial volume of healthy and arthrotic human knee joints]. Z. Orthop. Ihre Grenzgeb. 134(2), 144-148 (1996).
78. Vignon E, Balblanc JC, Mathieu P, Louisot P, Richard M: Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthr. Cartil. 1(2), 115-120 (1993).
79. Roosendaal G, Vianen ME, Marx JJ et al.: Blood-induced joint damage: a human in vitro study. Arthritis Rheum. 42(5), 1025-1032 (1999). (Pubitemid 29215015)
80. Hulejova H, Baresova V, Klezl Z et al.: Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 38(3), 151-156 (2007). (Pubitemid 47248299)
81. Stoop R, Albrecht D, Gaissmaier C et al.: Comparison of marker gene expression in chondrocytes from patients receiving autologous chondrocyte transplantation versus osteoarthritis patients. Arthritis Res. Ther. 9(3), R60 (2007).
82. Moos V, Fickert S, Muller B, Weber U, Sieper J: Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J. Rheumatol. 26(4), 870-879 (1999). (Pubitemid 29195675)
83. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J. Rheumatol. 24(2), 365-371 (1997). (Pubitemid 27104104)
84. Bertazzolo N, Punzi L, Stefani MP et al.: Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions 41(1-2), 90-92 (1994).
85. Neidel J, Schulze M, Sova L, Lindschau J: Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis. Z. Orthop. Ihre Grenzgeb. 134(4), 381-385 (1996).
86. Benton HP, Tyler JA: Inhibition of cartilage proteoglycan synthesis by interleukin I. Biochem. Biophys. Res. Commun. 154(1), 421-428 (1988).
87. Huch K, Wilbrink B, Flechtenmacher J et al.: Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1β. Arthritis Rheum. 40(12), 2157-2161 (1997). (Pubitemid 28016411)
88. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3(3), 168-177 (2001). (Pubitemid 32303433)
89. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthr. Cartil. 11(5), 335-342 (2003).
90. Shakibaei M, John T, Seifarth C, Mobasheri A: Resveratrol inhibits IL-1 β-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann. N Y. Acad. Sci. 1095, 554-563 (2007).
91. Interna F, DeGroot J, Elshof B et al.: The canine bilateral groove model of osteoarthritis. J. Orthop. Res. 26(11), 1471-1477 (2008).
92. van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB: Degenerative knee joint lesions in mice after a single intra-articular collagenase injection. A new model of osteoarthritis. J. Exp. Pathol. (Oxfoord) 71(1), 19-31 (1990).
93. Moskowitz RW, Davis W, Sammarco J et al.: Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum. 16(3), 397-405 (1973).
94. Chen LX, Lin L, Wang HJ et al.: Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-κBp65-specific siRNA. Osteoarthr. Cartil. 16(2), 174-184 (2008).
95. Pond MJ, Nuki G. Experimentally-induced osteoarthritis in the dog. Ann. Rheum. Dis. 32(4), 387-388 (1973).
96. Horiuchi T, Yoshida T, Koshihara Y et al.: The increase of parathyroid hormone-related peptide and cytokine levels in synovial fluid of elderly rheumatoid arthritis and osteoarthritis. Endocr.J. 46(5), 643-649 (1999).
97. Rodrigo JJ, Steadman JR, Syftestad G, Benton H, Silliman J: Effects of human knee synovial fluid on chondrogenesis in vitro. Am. J. Knee Surg. 8(4), 124-129 (1995). ■ One of the earlier studies in which the role of intra-articular injury and subsequent changes in synovial fluid composition on cartilage metabolism were recognized.
98. Fujita Y, Hara Y, Nezu Y, Schulz KS, Tagawa M: Proinflammatory cytokine activities, matrix metalloproteinase-3 activity, and sulfated glycosaminoglycan content in synovial fluid of dogs with naturally acquired cranial cruciate ligament rupture. Vet. Surg. 35(4), 369-376 (2006).
99. InnesJF, Sharif M, Barr AR: Changes in concentrations of biochemical markers of osteoarthritis following surgical repair of ruptured cranial cruciate ligaments in dogs. Am. J. Vet. Res. 60(9), 1164-1168 (1999).
100. Ley C, Ekman S, Elmen A, Nilsson G, Eloranta ml : Interleukin-6 and tumour necrosis factor in synovial fluid from horses with carpal joint pathology. J. Vet. Med. A. Physiol. Pathol. Clin. Med. 54(7), 346-351 (2007).
101. Fu LL, Maffulli N, Chan KM: Intra-articular hyaluronic acid following knee immobilisation for 6 weeks in rabbits. Clin. Rheumatol. 20(2), 98-103 (2001).
102. Williams JM, Ongchi DR, Thonar EJ: Repair of articular cartilage injury following intra-articular chymopapain-induced matrix proteoglycan loss. J. Orthop. Res. 11(5), 705-716 (1993).
103. Wei X, Messner K: Age- and injury-dependent concentrations of transforming growth factor-β 1 and proteoglycan fragments in rabbit knee joint fluid. Osteoarthr. Cartil. 6(1), 10-18 (1998).
104. Irie K, Uchiyama E, Iwaso H: Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 10(1), 93-96 (2003). (Pubitemid 36324521)
105. Higuchi H, Shirakura K, Kimura M et al.: Changes in biochemical parameters after anterior cruciate ligament injury. Int. Orthop. 30(1), 43-47 (2006).
106. Marks PH, Donaldson ml : Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament- deficient k nee. Arthroscopy 21(11), 1342-1347 (2005).
107. Yang KG, Saris DB, Verbout AJ, Creemers LB, Dhert WJ: The effect of synovial fluid from injured knee joints on in vitro chondrogenesis. Tissue Eng. 12(10), 2957-2964 (2006).
108. Schiff M, Minic M: Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J. Rheumatol. 31(7), 1373-1383 (2004). (Pubitemid 38879205)
109. Mastbergen SC, Lafeber FP, Bijlsma JW: Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 41(7), 801-808 (2002).
110. de Boer TN, Huisman AM, Polak AA et al.: The chondroprorective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthr. Cartil. 17(4), 482-488 (2008).
111. Curtis SP, Bockow B, Fisher C et al.: Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet. Disord. 6, 58 (2005).
112. Solomon SD, McMurray JJ, Pfeffer MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352(11), 1071-1080 (2005).
113. Clegg DO, Reda DJ, Harris CL et al.: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354(8), 795-808 (2006).
114. Arrich J, Piribauer F, Mad P etal: Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review andm eta-analysis. CMAJ. 172(8), 1039-1043 (2005).
115. Modawal A, Ferrer M, Choi HK, Castle JA: Hyaluronic acid injections relieve knee pain. J. Fam. Pract. 54(9), 758-767 (2005).
116. Bellamy N, Campbell J, Robinson V et al.: Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst. Rev. (2), CD005321 (2006).
117. Pal B, Morris J: Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists. Clin. Rheumatol. 18(3), 264-265 (1999).
118. Huang MH, Yang RC, Chou PH: Preliminary effects of hyaluronic acid on early rehabilitation of patients with isolated anterior cruciate ligament reconstruction. Clin. J. Sport Med. 17(4), 242-250 (2007).
119. Yang KG, Raijmakers NJ, van Arkel ER et al.: Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared with placebo in a prospective randomized controlled trial. Osteoarthr. Cartil. 16(4), 498-505 (2008).
120. Baltzer AW, Moser C, Jansen SA, Krauspe R: Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthr. Cartil. (2008).
121. Chevalier X, Goupille P, Beaulieu AD et al.: Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (Kineret®) in patients with osteoarthritis of the knee. Arthritis Rheum. 52(9), S507-S507 (2005).
122. Pelletier JP, Caron JP, Evans C et al.: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 40(6), 1012-1019 (1997).
123. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P: The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm. Res. 52(10), 404-407 (2003).
124. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW: Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am. J Vet. Res. 68(3), 290-296 (2007).
125. Yang KG, Raijmakers NJ, van Arkel ER et al.: Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared with placebo in a prospective randomized controlled trial. Osteoarthr. Cartil. 16(4), 498-505 (2008).
126. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M: The placebo effect and its determinants in osteoarthritis - meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 67(12), 1716-1723 (2008).
127. Fu X, Lin L, Zhang J, Yu C: Assessment of the efficacy of joint lavage in rabbits with osteoarthritis of the knee. J. Orthop. Res. 27(1), 91-96 (2009).
128. Richette P, Francois M, Vicaut E et al.: A high interleukin 1 receptor antagonist/IL-1β ratio occurs naturally in knee osteoarthritis. J. Rheumatol. 35(8), 1650-1654 (2008).
129. Wehling P, Moser C, Frisbie D et al.: Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs 21(5), 323-332 (2007). (Pubitemid 47529471)
130. Blumenauer B, Judd M, Cranney A et al.: Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. (4), CD004525 (2003).
131. Grunke M, Schulze-Koops H: Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann. Rheum. Dis. 65(4), 555-556 (2006).
132. Cytokines induce inflammation and cartilage degradation. Oral TNF-α blocker against arthrosis. MMW Fortschr. Med. 144(15), 64 (2002).
133. Webb GR, Westacott CI,Elson CJ: Osteoarthritic synovial fluid and synovium supernatants up-regulate tumor necrosis factor receptors on human articular chondrocytes. Osteoarthr. Cartil. 6(3), 167-176 (1998).
134. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E: Effects of TNFα-antagonists on nitric oxide production in human cartilage. Osteoarthr. Cartil. 10(4), 327-332 (2002).
135. Bongartz T, Sutton AJ, Sweeting MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275-2285 (2006). (Pubitemid 43736578)
136. Burstein D, Velyvis J, Scott KT et al.: Protocol issues for delayed Gd(DTPA) (2-)-enhanced MRI (dGEMRIC) for clinical evaluation of articular cartilage. Magn. Reson. Med. 45(1), 36-41 (2001). ■ Clear explanation of a promising and currently broadly recognized technique for the noninvasive imaging of cartilage by delayed gadolinium-enhanced MRI of cartilage (dGEMRIC).
137. Young AA, Stanwell P, Williams A et al.: Glycosaminoglycan content of knee cartilage following posterior cruciate ligament rupture demonstrated by delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC). A case report. J. Bone Joint Surg. Am. 87(12), 2763-2767 (2005).
138. Azuma J, Ogura M, Yamamoto I et al.: The effect of Y-25510 injection on the serum levels of some cytokines in healthy adult volunteers. Eur. J. Clin. Pharmacol. 53(6), 411-419 (1998).
139. Kutukculer N, Caglayan S, Aydogdu F: Study of pro-inflammatory (TNF-α, IL-1α, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol. 17(4), 288-292 (1998).
140. Matsuzaki T, Nakajima A, Ishigami S, Tanno M, Yoshino S: Mirthful laughter differentially affects serum pro- and anti-inflammatory cytokine levels depending on the level of disease activity in patients with rheumatoid arthritis. Rheumatology (Oxford) 45(2), 182-186 (2006). (Pubitemid 43160080)
141. Robak T, Wierzbowska A, Blasinska-Morawiec M, Korycka A, Blonski JZ: Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm. 8(6), 277-286 (1999). (Pubitemid 30232873)
142. Darcissac EC, Vidal V, De La Tribonniere X, Mouton Y, Bahr GM: Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin. Exp. Immunol. 126(2), 287-294 (2001).
143. + T cells and macrophages. Arthritis Rheum. 52(6), 1700-1710 (2005).
144. Rysz J, Banach M, Cialkowska-Rysz A et al.: Blood serum levels of IL-2, IL-6,IL-8, TNF-α and IL-1β in patients on maintenance hemodialysis. Cell Mol. Immunol. 3(2), 151-154 (2006).
145. Lee YC, Lee KH, Lee HB, Rhee YK: Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-γ in acute asthma. J. Asthma 38(8), 665-671 (2001).
146. Haznedaroglu S, Ozturk MA, Sancak B et al.: Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin. Exp. Rheumatol. 23(4 Suppl 38), S77-80 (2005).
147. Agarwal S, Misra R, Aggarwal A: Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 35(3), 515-519 (2008).
148. Martini G, Gennari L, Merlotti D et al.: Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40(2), 457-463 (2007). (Pubitemid 46054544)
149. Manicourt DH, Poilvache P, Van Egeren A et al.: Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum. 43(2), 281-288 (2000). (Pubitemid 30395736)
150. Okamoto H, Yamamura M, Morita Y et al.: The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 40(6), 1096-1105 (1997). (Pubitemid 27242297)
151. Czarkowska-Paczek B, Bartlomiejczyk I, Przybylski J: The serum levels of growth factors: PDGF, TGF-β and VEGF are increased after strenuous physical exercise. J. Physiol. Pharmacol. 57(2), 189-197 (2006).
152. Colangelo LA, Chiu B, Kopp P, Liu K, Gapstur SM: Serum IGF-I and C-reactive protein in healthy black and white young men: The CARDIA male hormone study. Growth Horm. IGF Res. (2009).
153. Tavera C, Abribat T, Reboul P et al.: IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients.